Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Earnings for Regulus Therapeutics Inc. (RGLS)
Earnings in 2023 (TTM): $-30,036,000
According to Regulus Therapeutics Inc.'s latest financial reports the company's current earnings (TTM) are $-30,036,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Regulus Therapeutics Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-30,036,000 | $-30,037,000 |
| 2022 | $-28,322,000 | $-28,323,000 |
| 2021 | $-27,807,000 | $-27,808,000 |
| 2020 | $-15,730,000 | $-15,263,000 |
| 2019 | $-18,591,000 | $-18,592,000 |
| 2018 | $-48,647,000 | $-48,709,000 |
| 2017 | $-72,102,000 | $-71,905,000 |
| 2016 | $-81,840,000 | $-81,836,000 |
| 2015 | $-55,766,000 | $-55,748,000 |
| 2014 | $-56,679,000 | $-56,680,000 |
| 2013 | $-18,691,000 | $-18,668,000 |
| 2012 | $-17,418,000 | $-17,408,000 |
| 2011 | $-7,396,000 | $-7,602,000 |
| 2010 | $-15,589,000 | $-15,559,000 |